
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): February 22, 2008

EXACTECH, INC.

(Exact Name of Registrant as Specified in Its Charter)

Florida	0-28240	59-2603930
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**2320 NW 66th Court
Gainesville, Florida 32653**

(Address of Principal Executive Office)

Registrant's telephone number, including area code (352) 377-1140

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure

On February 27, 2008, the Company issued a press release announcing its entry into a share purchase agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 8.01. Other Events

On February 22, 2008, Exactech, Inc., a Florida corporation (the “Company”), entered into a share purchase agreement (“Purchase Agreement”) between the Company and the shareholders of France Medica, a French simplified joint-stock company (“France Medica”), for the purchase of 100% of the shares of France Medica. France Medica has worked with the Company as a distributor of Exactech products in France for a number of years.

The aggregate purchase price is expected to range between approximately €6.8 million and €7.1 million, or approximately \$10.1 million and \$10.5 million, respectively, based on an exchange rate of \$1.48 per €1.00 on February 25, 2008. The Company will pay a fixed price of €5.4 million, or approximately \$8.0 million, approximately €4.8 million, or \$7.1 million, of which is payable to certain shareholders in cash and €89,923, or approximately \$873,100 of which, is payable to certain shareholders in shares of Exactech common stock, par value \$0.01 per share (“Common Stock”), using a per share value equal to the ninety trading day average closing price of one share of Common Stock as of the closing date. A price supplement of between €1.4 million and €1.7 million, or \$2.1 million and \$2.5 million, is payable to certain shareholders of France Medica, over a two year period, if certain conditions of employment and sales results are achieved in each of the annual periods. If the conditional terms are not met, the supplemental payment will be reduced by up to 50%. The Common Stock to be issued as partial proceeds for the acquisition will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws and will not be able to be sold except in a transaction registered under, or exempt from, the registration provisions of the Securities Act and applicable state securities laws. Closing of the acquisition is anticipated during the second quarter 2008, and completion is subject to the customary closing conditions.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release issued by the Company on February 27, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXACTECH, INC.

Date: February 27, 2008

By: /s/ Joel C. Phillips
Joel C. Phillips
Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release issued by the Company on February 27, 2008.



2320 NW 66th COURT
 GAINESVILLE, FL 32653
 PHONE: 352-377-1140
 FAX: 352-378-2617



Investor Relations Contact:
 Hawk Associates, Inc.
 Julie Marshall and Frank Hawkins
 Phone: 305- 451-1888
 E-mail: info@hawkassociates.com
<http://www.hawkassociates.com>

**News Release:
 FOR IMMEDIATE RELEASE**

Exactech to Acquire Distribution Company in France; Opens Direct Distribution Operations in Japan

GAINESVILLE, Fla. -- February 27, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today the opening of a wholly-owned distribution subsidiary in Japan and the planned acquisition of a distribution subsidiary in France. Japan and France are two of the largest orthopaedic device markets outside the United States.

Exactech said it will acquire the stock and assets of France Medica SAS, a Strasbourg-based importer and distributor of orthopaedic products and surgical supplies. The total purchase price is projected to be 6.8 million to 7.1 million euros. Exactech expects France Medica's full year 2008 revenues will be approximately 8.0 million euros. The purchase price for France Medica involves 5.4 million euros to be paid upon closing and 1.4 million to 1.7 million euros in earn-out payments based on the performance of France Medica over the next two years. Exactech expects the transaction to be neutral to earnings in 2008 and accretive in 2009. The closing is expected to be completed in the second quarter of 2008.

Exactech also said it has finalized arrangements to create a direct distribution operation in Japan, where it previously sold its products through a distributor. The direct operation sales and logistics subsidiary based in Tokyo enables Exactech to directly control its Japanese marketing and distribution operations. The venture will be headed by Kunio Watanabe, a seasoned orthopaedic marketing executive who has more than 14 years of experience distributing medical products in Japan for U.S. and European companies.

President David Petty said, "France Medica has been a valuable and key strategic partner for a number of years. In addition to distributing our Optetrak® knee system, France Medica also provides hips, shoulders, trauma products and instrumentation sets for clinics and hospitals throughout France. We believe we can better serve our French customers by establishing a direct operation in this important market. France Medica currently employs approximately 25 distribution and sales professionals and we are delighted that key members of France Medica's existing management team will stay on as part of the new Exactech subsidiary.

"We have been selling products in Japan through a distributor agreement for over a decade. This new arrangement will allow for continuation of this important relationship while also creating an opportunity for Exactech to expand its market presence in Japan with a new team of seasoned orthopaedic sales professionals in the direct operation. We are enthusiastic about expanding our global presence in the orthopaedic market."

More details on Exactech's international expansion will be discussed on the company's 2007 earnings conference call on February 29, 2008 at 11:00 a.m. Eastern time. Exactech will release its fourth-quarter and 2007 year-end earnings on Thursday, February 28, after the market closes.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech's orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States and Australia, in addition to more than 25 countries in Europe, Asia and Latin America. Additional information about Exactech, Inc. can be found at <http://www.exac.com>. Copies of Exactech's press releases, SEC filings, current price quotes and other valuable information for investors may be found at <http://www.exac.com> and <http://www.hawkassociates.com>.

An investment profile on Exactech may be found at <http://www.hawkassociates.com/exacprofile.aspx>

Investors may contact Chief Financial Officer Jody Phillips at 352-377-1140 or Julie Marshall or Frank Hawkins, Hawk Associates Inc., at 305-451-1888, e-mail: info@hawkassociates.com. To receive future releases in e-mail alerts, sign up at <http://www.hawkassociates.com/email.aspx>.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company's expectations or beliefs concerning future events of the company's financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company's dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company's products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.